Specifica, a IQVIA Laboratories company, is applying its proven platform for antibody discovery to generate recombinant monoclonal antibody reagents. Our in vitro display approach eliminates the need for immunization, addressing animal welfare concerns and insufficient quantities of antigen. Delivery of recombinant sequences ensures higher specificity and reproducibility than animal-based methods, as well as the ability to easily engineer these reagents. Our services include:
- Tool reagents to validate your discovery research
- Anti-idiotypes (anti-ids) for drug discovery
Download Document
Related Insights
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
Bioanalytical Automation of Samples
Taking an assay from bench to an automated platform
Automation within an ADME Laboratory
Taking an assay from bench to an automated platform
Bioanalytical Automation of Samples
Taking an assay from bench to an automated platform
Developing Assays for Novel Drugs
Current science regarding hybrid assays, why they are considered the next "big thing," the technical challenges, and the regulatory impact of these assays.
Strategies for Effective Neutralizing Cell Based Assays in Early Immunogenicity Risk Assessment
Quantitative Assays for Peptides using LC-MS
Quantitative high-throughput analysis of peptide therapeutics and biomarkers to regulated bioanalytical standards
Hybrid Assays for Protein Bioanalysis
Combining immuno-affinity with liquid chromatography-mass spectrometry (LC-MS)
Absolute Bioavailability Analysis Using Stable Isotopes
A Liquid Chromatography-Tandem Mass Spectrometry Approach
Bioanalysis for Immuno Oncology with Mike Brown
I-O clinical development podcast series
